Journal Cover Nature Reviews Drug Discovery
  [SJR: 11.742]   [H-I: 235]   [337 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1474-1776 - ISSN (Online) 1474-1784
   Published by NPG Homepage  [135 journals]
  • Morgan Sheng
    • Morgan Sheng

      Morgan Sheng, Published online: 19 January 2018; doi:10.1038/nrd.2017.271

      Morgan Sheng, Vice President of Neuroscience at Genentech, discusses his continued faith in the amyloid hypothesis, the promise of the genetics of neurodegenerative disorders and the overlap between psychiatric disease and neurodegeneration.Morgan Sheng, Published online: 2018-01-19; doi:10.1038/nrd.2017.2712018-01-19
      DOI: 10.1038/nrd.2017.271
       
  • Impact of a five-dimensional framework on R&D productivity at
           AstraZeneca
    • Impact of a five-dimensional framework on R&D productivity at AstraZeneca

      Impact of a five-dimensional framework on R&D productivity at AstraZeneca, Published online: 19 January 2018; doi:10.1038/nrd.2017.244

      In 2011, AstraZeneca set out to improve its research and development (R&D) productivity by focusing decision-making using a framework with five technical determinants: the right target, right tissue, right safety, right patient and right commercial potential. Here, Pangalos and colleagues describe the progress made using this '5R framework', with metrics indicating improved success rates, and discuss where the approach has failed and the lessons learned.Impact of a five-dimensional framework on R&D productivity at AstraZeneca, Published online: 2018-01-19; doi:10.1038/nrd.2017.2442018-01-19
      DOI: 10.1038/nrd.2017.244
       
  • Glimmers in illuminating the druggable genome
    • Glimmers in illuminating the druggable genome

      Glimmers in illuminating the druggable genome, Published online: 19 January 2018; doi:10.1038/nrd.2017.252

      Much biomedical research continues to focus on a small proportion of the human genome that has already been studied intensively. The Illuminating the Druggable Genome programme, initiated as a pilot project by the US National Institutes of Health Common Fund in 2014, is now being implemented to accelerate the investigation of subsets of understudied proteins that have potential therapeutic relevance.Glimmers in illuminating the druggable genome, Published online: 2018-01-19; doi:10.1038/nrd.2017.2522018-01-19
      DOI: 10.1038/nrd.2017.252
       
  • Market watch: 2017 FDA drug approvals: number rebounds but average value
           slips
    • Market watch: 2017 FDA drug approvals: number rebounds but average value slips

      Market watch: 2017 FDA drug approvals: number rebounds but average value slips, Published online: 19 January 2018; doi:10.1038/nrd.2018.2

      Market watch: 2017 FDA drug approvals: number rebounds but average value slipsMarket watch: 2017 FDA drug approvals: number rebounds but average value slips, Published online: 2018-01-19; doi:10.1038/nrd.2018.22018-01-19
      DOI: 10.1038/nrd.2018.2
       
  • 2017 FDA drug approvals
    • 2017 FDA drug approvals

      2017 FDA drug approvals, Published online: 19 January 2018; doi:10.1038/nrd.2018.4

      The FDA approved 46 new drugs last year, the highest total in more than two decades.2017 FDA drug approvals, Published online: 2018-01-19; doi:10.1038/nrd.2018.42018-01-19
      DOI: 10.1038/nrd.2018.4
       
  • mRNA vaccines — a new era in vaccinology
    • mRNA vaccines — a new era in vaccinology

      mRNA vaccines — a new era in vaccinology, Published online: 12 January 2018; doi:10.1038/nrd.2017.243

      mRNA vaccines represent a promising alternative to conventional vaccine approaches, but their application has been hampered by instability and delivery issues. Here, Pardi and colleagues discuss recent advances in mRNA vaccine technology, assess mRNA vaccines currently in development for cancer and infectious diseases and consider future directions and challenges.mRNA vaccines — a new era in vaccinology, Published online: 2018-01-12; doi:10.1038/nrd.2017.2432018-01-12
      DOI: 10.1038/nrd.2017.243
       
  • Biased signalling: from simple switches to allosteric microprocessors
    • Biased signalling: from simple switches to allosteric microprocessors

      Biased signalling: from simple switches to allosteric microprocessors, Published online: 05 January 2018; doi:10.1038/nrd.2017.229

      A given G protein-coupled receptor can signal through a range of downstream transducers depending on the stimulating ligand, enabling biased signalling towards different biological outcomes. Lefkowitz and colleagues describe the latest advances in the field, including efforts to harness biased signalling for improved therapeutic outcomes.Biased signalling: from simple switches to allosteric microprocessors, Published online: 2018-01-05; doi:10.1038/nrd.2017.2292018-01-05
      DOI: 10.1038/nrd.2017.229
       
  • Accelerated approval of medicines: fit for purpose'
    • Accelerated approval of medicines: fit for purpose?

      Accelerated approval of medicines: fit for purpose?, Published online: 05 January 2018; doi:10.1038/nrd.2017.245

      The uptake of a new medicine represents a balance between benefit–risk assessment and value considerations. In the case of products approved via accelerated pathways, the increased uncertainty adds to the challenge. Here, we suggest solutions so that regulators, companies, payers and patients can align around management of the uncertainties and expectations.Accelerated approval of medicines: fit for purpose?, Published online: 2018-01-05; doi:10.1038/nrd.2017.2452018-01-05
      DOI: 10.1038/nrd.2017.245
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.82.57.154
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016